Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.62 |
| ▸ | AR | P10275 | 13/20 | 0.60 |
| ▸ | TNKS | O95271 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546606 | 1.00 | PGR (0.62) | PGRARTNKSPARP1PARP2 | |
| SCHEMBL28538027 | 1.00 | PGR (0.62) | PGRARTNKSPARP1PARP2 | |
| SCHEMBL20046695 | 1.00 | PGR (0.62) | PGRARTNKSPARP1PARP2 | |
| SCHEMBL31604723 | 0.87 | PGR (0.46) | PGRAREPHX2DRD2 | |
| SCHEMBL6154916 | 0.87 | KDM4D (0.47) | PGRAREPHX2DRD2 | |
| SCHEMBL6154808 | 0.86 | SUV39H2 (0.46) | PGRARDRD2 | |
| SCHEMBL30588163 | 0.85 | AR (0.53) | PGRAREPHX2 | |
| SCHEMBL29547208 | 0.85 | AR (0.67) | PGRARTNKSPARP1PARP2 | |
| SCHEMBL22565382 | 0.84 | AR (0.74) | AR | |
| SCHEMBL31515461 | 0.84 | EPHX2 (0.48) | PGRAREPHX2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | PGR 300/4885AR 1/4885TNKS 2556/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | PGR 311/4885AR 1/4885TNKS 2586/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | PGR 300/4885AR 1/4885TNKS 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.